



SCC and BCC Guidelines – Follow-Up Recommendations 2023

These guidelines for follow-up after diagnosing squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) are not intended as exact and are not a substitute for clinical decision-making. They are a summary based on the National Comprehensive Cancer Network (NCCN) Guidelines,^{6,7} Australian Cancer Council – Clinical Practice Guidelines for Keratinocyte Cancer⁸ and the 2017 American Joint Committee on Cancer (AJCC) Staging Manual.⁹

Follow-up should include the following:

- Assessment of the lesion excision site for recurrence and regional disease.
- Patient education: sun protection, skin self-examination, and examination of lymph nodes if high-risk or metastatic SCC.
- Consideration of referral for imaging if the clinical examination is insufficient.

Note: the following recommended follow-up intervals are a minimum. A shorter follow-up interval may be appropriate if the patient has or has had multiple lesions of concern or is immunosuppressed.

Where practical, clinicians should provide education and encourage patients to have full skin checks. Patients with a single non-melanoma skin cancer (NMSC) have an increased relative risk of melanoma and other NMSCs compared with patients without such a history.

BCC *

6–12 monthly for the first five years, and then at least annually for life.

3–6 months after cessation of topical treatment of superficial BCC.

SCC *

Local disease

Low-risk patients: 6–12 monthly for five years, then at least annually for life.

High-risk patients: 3–6 monthly for two years, six monthly for three years, then annually for life.



Regional disease

Three monthly for one year, four monthly for one year, six monthly for three years, and then annually for life.

*After a single BCC or SCC, there is a 10-fold increase compared to the general population of developing another BCC or SCC, respectively.^{1,4} 13–50% of patients diagnosed with cutaneous SCC will develop another SCC within five years, and an estimated 30–50% of BCC patients will develop another BCC in the same period.^{1,2,3,4} In addition, prior SCC increases the future risk of BCC, and to a lesser extent, previous BCC increases the risk of SCC.^{1,4} After NMSC, there is also a four-fold increase in the diagnosis of melanoma compared to the general population.^{2,4} There is an increased risk of a BCC in the short-term follow-up period following initial BCC,³ and 70–80% of recurrences of cutaneous SCC develop within two years of the initial treatment.⁵ Therefore, close early follow-up (within two years) is essential.



References

1. Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. *Arch Dermatol* 2000;136:1524-1530.
<http://www.ncbi.nlm.nih.gov/pubmed/11115165>.
2. Karagas MR, Stukel TA, Greenberg ER, et al. Risk of subsequent basal cell carcinoma and squamous cell carcinoma of the skin among patients with prior skin cancer. Skin Cancer Prevention Study Group. *JAMA* 1992;267:3305-3310.
<http://www.ncbi.nlm.nih.gov/pubmed/1597912>.
3. Flohil SC, Koljenovic S, de Haas ER, et al. Cumulative risks and rates of subsequent basal cell carcinomas in the Netherlands. *Br J Dermatol* 2011;165:874-881.
<http://www.ncbi.nlm.nih.gov/pubmed/21711333>.
4. Flohil SC, van der Leest RJ, Arends LR, et al. Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: a systematic review and meta-analysis. *Eur J Cancer* 2013;49:2365- 2375.
<http://www.ncbi.nlm.nih.gov/pubmed/23608733>.
5. Levine DE, Karia PS, Schmults CD. Outcomes of Patients With Multiple Cutaneous Squamous Cell Carcinomas: A 10-Year Single Institution Cohort Study. *JAMA Dermatol* 2015;151:1220-1225.
<http://www.ncbi.nlm.nih.gov/pubmed/26177278>.
6. National Comprehensive Cancer Network Guidelines Version 1.2023 Squamous Cell Skin Cancer.
https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf
7. National Comprehensive Cancer Network Guidelines Version 1.2023 Basal Cell Skin Cancer.
https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf
8. Australian Cancer Council – Clinical Practice Guidelines for Keratinocyte Cancer.
https://wiki.cancer.org.au/australia/Guidelines:Keratinocyte_carcinoma
9. *2017 AJCC Staging Manual*.